Ab0017 t Helper /Regulatory T Cells Ratios Imbalance in Different Staging Rheumatoid Arthritis

Abstract

BackgroundRheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that results in the destruction of the bone and cartilage of the joints[1].The imbalance between Th17 and Treg cells has been demonstrated to play a role in RA pathogenesis[2].With the advances in the RA field, curing and even preventing RA has become a new direction of efforts. To explore the immune characteristics in multi-staging RA is helpful for the development of accurate strategies.ObjectivesTo observe the immune characteristics in different staging rheumatoid arthritis patientsMethodsA total of 127 patients with RA were recruited for this study, in cluding 30 early RA(newly diagnosed and treatment-naive,duration of disease ≤3months), 30 midddle RA (newly diagnosed and treatment-naive, duration of disease >3months and≤1 year), 30 advanced RA(newly diagnosed and treatment-naive,duration of disease >1 year) and 37 active treated RA (remissioned after target treatment and this time due to disease recurrence in hospital). All patients were hospitalized in the second hospital of Shanxi medical university and diagnosed with RA fulfilled the ACR 1987 or 2010 criteria.The percentage and absolute numbers of lymphocyte phenotypes and CD4+ T subsets in peripheral blood were examined by flow cytometry.ResultsThere were no significant difference in the percentage and value of T,B,NK,CD4+T,CD8+T andCD4+T subsets. But the Th1/Th2 cell ratios in active treated RA group were increased than that in early RA, middle RA and advanced RA group.The Th17/Treg cell ratios in middle RA and advanced RA group were higher when compared with those of active treated RA group.In addition, the Th1/ Treg cell ratios were decreased in middle and advanced RA group as compared with those in active treated RA.ConclusionTh1/Th2,Th17/Treg and Th1/Treg imbalance varied with disease staging.The different disease staging in RA, the immune function is different. Providing targeted immunotherapy according to disease staging is helpful to improve remission rates and even prevent disease.References[1]Petrovská N, Prajzlerová K, Vencovský J, Šenolt L, Filková M.The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis.Autoimmun Rev.2021, 20(5):102797.[2]Alison M Gizinski, David A Fox.T cell subsets and their role in the pathogenesis of rheumatic disease.Curr Opin Rheumatol,2014;26(2):204-10.Figure 1.The comparsion about the lymphocyte subsets and cell ratios in peripheral blood of different stage RA patients.(*p<0.05)Disclosure of InterestsNone declared